Faruqi & Faruqi Issues Formal Notice to Ultragenyx (RARE) Investors

On February 19, 2026, national securities litigation firm Faruqi & Faruqi, LLP issued an official investor alert reminding shareholders of Ultragenyx Pharmaceutical Inc. (traded on NASDAQ under the ticker RARE) about the upcoming April 6, 2026 deadline to participate in a federal securities class action lawsuit. The notice was released via GlobeNewswire, a financial news distribution platform.

Purpose of the Notice

The law firm is investigating potential legal claims against Ultragenyx and its executives for allegedly violating federal securities laws. Specifically, Faruqi & Faruqi is encouraging investors who suffered losses from buying or acquiring Ultragenyx securities between August 3, 2023 and December 26, 2025 to contact the firm, discuss their rights, and consider seeking the role of lead plaintiff in the class action.

How Investors Can Respond

Investors who believe they were harmed by the company’s alleged misrepresentations can reach out directly to Faruqi & Faruqi’s securities litigation partner, James (Josh) Wilson, for legal guidance. The firm provides toll-free and direct office contact numbers for consultations.

Key Contact Information (as provided in the notice)

• Phone (Toll-free): 877-247-4292
• Office: 212-983-9330 Ext. 1310
• Website for case details: www.faruqilaw.com/RARE

These channels are offered for both direct inquiries and to learn more about the class action process.

Allegations in the Class Action Complaint

The central allegations in the lawsuit claim that Ultragenyx and certain of its senior executives made false or misleading statements — or failed to disclose material information — related to the company’s clinical trial results for its experimental biologic drug, setrusumab. The suit argues that investors were given a misleading impression regarding the reliability of data from clinical trials, specifically the Phase III ORBIT and COSMIC studies.

Misleading Statements and Clinical Trial Risks

According to the complaint:

• Ultragenyx allegedly created an unjustified impression of positive results from clinical research on setrusumab for Osteogenesis Imperfecta, a rare bone disorder.
• The company allegedly minimized or failed to disclose the significant risk that the ORBIT study might not achieve a statistically significant reduction in fracture rates.
• Part of the criticism focuses on the use of Phase II data that had no placebo control group, limiting the reliability of comparisons and raising concerns about the validity of conclusions drawn from that data.

Key Events Affecting Ultragenyx Stock Price

The complaint highlights two primary events during the class period that had significant impacts on the company’s stock price:

1. July 9, 2025 Announcement

Ultragenyx disclosed that its Phase III ORBIT trial did not meet the required statistical significance for its interim analysis. The company stated that both ORBIT and COSMIC trials would continue toward their final analyses. This news reportedly triggered a more than 25% decline in the company’s stock price.

2. December 29, 2025 Results

Ultragenyx then revealed that both pivotal Phase III trials (ORBIT and COSMIC) failed to achieve statistical significance against their primary endpoints — specifically, reducing the annualized clinical fracture rate compared to placebo or existing treatments. The stock fell again — reportedly by over 42% on that news.

Understanding Lead Plaintiff Process

In federal securities class actions, the lead plaintiff represents the interests of the entire class of investors. The role typically goes to the investor or group with the largest financial interest and who can adequately represent the class.

Shareholders may:

• File a motion with the court to serve as lead plaintiff before April 6, 2026.
• Select counsel of choice, subject to the court’s approval.
• Choose not to participate in leadership and remain a passive class member.

Additional Encouragement

Faruqi & Faruqi also invites anyone with information about Ultragenyx’s conduct — including whistleblowers, former employees, or other shareholders — to contact the firm. This approach is common in securities litigation, where insider knowledge may help strengthen claims.

About Faruqi & Faruqi, LLP

Faruqi & Faruqi is a well-known national securities law firm with offices across the United States, including in New York, Pennsylvania, California, and Georgia. Since its founding in 1995, the firm has recovered hundreds of millions of dollars for investors in securities litigation matters.

What Investors Should Do Now

Investors who fall within the defined class period and suffered losses are advised to consult with legal counsel without delay to protect their rights and consider the benefits and responsibilities of seeking lead plaintiff status.

#UltragenyxRARE #SecuritiesClassAction #InvestorDeadline #FaruqiLaw #SlimScan #GrowthStocks #CANSLIM